McFarland Melinda A, Ellis Christopher E, Markey Sanford P, Nussbaum Robert L
National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20891, USA.
Mol Cell Proteomics. 2008 Nov;7(11):2123-37. doi: 10.1074/mcp.M800116-MCP200. Epub 2008 Jul 9.
Mutations and copy number variation in the SNCA gene encoding the neuronal protein alpha-synuclein have been linked to familial Parkinson disease (Thomas, B., and Beal, M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16, R183-R194). The carboxyl terminus of alpha-synuclein can be phosphorylated at tyrosine 125 and serine 129, although only a small fraction of the protein is phosphorylated under normal conditions (Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397). Under pathological conditions, such as in Parkinson disease, alpha-synuclein is a major component of Lewy bodies, a pathological hallmark of Parkinson disease, and is mostly phosphorylated at Ser-129 (Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J. P., Kling, K., Lee, M., Diep, L., Keim, P. S., Shen, X. F., Chataway, T., Schlossmacher, M. G., Seubert, P., Schenk, D., Sinha, S., Gai, W. P., and Chilcote, T. J. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752). Controversy exists over the extent to which phosphorylation of alpha-synuclein and/or the visible protein aggregation in Lewy bodies are steps in disease pathogenesis, are protective, or are neutral markers for the disease process. Here we used the combination of peptide pulldown assays and mass spectrometry to identify and compare protein-protein interactions of phosphorylated and non-phosphorylated alpha-synuclein. We showed that non-phosphorylated alpha-synuclein carboxyl terminus pulled down protein complexes that were highly enriched for mitochondrial electron transport proteins, whereas alpha-synuclein carboxyl terminus phosphorylated on either Ser-129 or Tyr-125 did not. Instead the set of proteins pulled down by phosphorylated alpha-synuclein was highly enriched in certain cytoskeletal proteins, in vesicular trafficking proteins, and in a small number of enzymes involved in protein serine phosphorylation. This targeted comparative proteomics approach for unbiased identification of protein-protein interactions suggests that there are functional consequences when alpha-synuclein is phosphorylated.
编码神经元蛋白α-突触核蛋白的SNCA基因中的突变和拷贝数变异与家族性帕金森病有关(托马斯,B.,和比尔,M.F.(2007年)帕金森病。《人类分子遗传学》16,R183 - R194)。α-突触核蛋白的羧基末端可在酪氨酸125和丝氨酸129处被磷酸化,尽管在正常条件下只有一小部分蛋白质被磷酸化(大越,M.,沃尔特,J.,小山,A.,中条,S., Baba,M.,岩津,T.,梅杰,L.,卡勒,P.J.,和哈斯,C.(2000年)帕金森病相关α-突触核蛋白的组成性磷酸化。《生物化学杂志》275,390 - 397)。在病理条件下,如在帕金森病中,α-突触核蛋白是路易小体的主要成分,路易小体是帕金森病的病理标志,并且大多在丝氨酸129处被磷酸化(安德森,J.P.,沃克,D.E.,戈尔茨坦,J.M.,德·拉特,R.,班杜奇,K.,卡卡韦洛,R.J.,巴伯,R.,黄,J.P.,克林,K.,李,M.,迪普,L.,凯姆,P.S.,沈,X.F.,查塔韦,T.,施洛斯马赫,M.G.,休伯特,P.,申克,D.,辛哈,S.,盖,W.P.,和奇尔科特,T.J.(2006年)丝氨酸129的磷酸化是家族性和散发性路易小体病中α-突触核蛋白的主要病理修饰。《生物化学杂志》281,29739 - 29752)。关于α-突触核蛋白的磷酸化和/或路易小体中可见的蛋白质聚集在疾病发病机制中是步骤、是保护性的还是疾病过程的中性标志物,存在争议。在这里,我们使用肽下拉分析和质谱联用的方法来鉴定和比较磷酸化和未磷酸化的α-突触核蛋白的蛋白质 - 蛋白质相互作用。我们发现未磷酸化的α-突触核蛋白羧基末端下拉的蛋白质复合物高度富集线粒体电子传递蛋白,而在丝氨酸129或酪氨酸125处磷酸化的α-突触核蛋白羧基末端则没有。相反,磷酸化的α-突触核蛋白下拉的蛋白质组高度富集某些细胞骨架蛋白、囊泡运输蛋白以及少数参与蛋白质丝氨酸磷酸化的酶。这种用于无偏鉴定蛋白质 - 蛋白质相互作用的靶向比较蛋白质组学方法表明,α-突触核蛋白磷酸化会产生功能后果。